ACRS — Aclaris Therapeutics Share News
0.000.00%
Last trade - 00:00- $628.49m
- $523.07m
- $7.83m
Brief: Aclaris Therapeutics Q1 Net Income USD -15.085 Million Vs. IBES Estimate USD -13.3 Million
Aclaris Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Brief: Aclaris Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Aclaris Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Aclaris Therapeutics Q4 Revenue USD 9.211 Million Vs. IBES Estimate USD 2.11 Million
Aclaris Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Walmart, Fiserv, Rumble
U.S. STOCKS ON THE MOVE-Nordstrom, Optical Cable, Lexicon
U.S. STOCKS ON THE MOVE-Eli Lilly, Playa Hotels, Rumble
Aclaris Therapeutics gains after H.C. Wainwright upgrades to 'buy'
Brief: Aclaris Therapeutics Inc -Files Prospectus For Offer, Resale By Selling Stockholders Of Up To 35.6 Million Shares Of Common Stock
Brief: Aclaris Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target
Aclaris soars after multiple brokerages upgrade ratings following key deal
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
Aclaris rises after securing rights to two experimental immunology drugs
Brief: Aclaris Therapeutics Announces Exclusive, Global License Agreement With Biosion